|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer-Related Problem/Condition | |||||
| Leukemia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Leukemia, Large Granular Lymphocytic | |||||
| Leukemia, Lymphoid | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Leukemia, T-Cell | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| cyclosporine | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Cyclosporins | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antifungal Agents | |||||
| Antirheumatic Agents | |||||
| Dermatologic Agents | |||||
| Enzyme Inhibitors | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Cancer and Leukemia Group B | |||||
| National Cancer Institute (NCI) | |||||